EyePoint, Inc. provided a corporate update and outlined pivotal milestones for 2026 for its lead product candidate, DURAVYU.
The company highlighted Phase 3 programs for DURAVYU in wet AMD and DME, targeting large retinal disease markets.
EyePoint aims to deliver topline data from its Phase 3 wet AMD program in mid-2026 and expects to dose the first patient in the Phase 3 DME program in Q1 2026.
Phase 3 Trials Progress
Pivotal Phase 3 trials for wet AMD are on track for data readout beginning in mid-2026, with the first patient dosing in the DME program expected in Q1 2026.
Corporate Focus
EyePoint remains focused on advancing DURAVYU as a best-in-class and first-in-class sustained delivery therapy for serious retinal diseases.
Enrollment Success
The Phase 3 LUGANO and LUCIA trials enrolled over 900 patients in 7 months, positioning DURAVYU potentially as first to market among sustained delivery programs for wet AMD.
- DURAVYU's unique multi-mechanism of action and strong enrollment rates in Phase 3 trials indicate a promising outlook for EyePoint in 2026.
- The company's commitment to scientific rigor and patient-centric focus underscores its dedication to improving treatments for retinal diseases.
With significant progress in Phase 3 trials and promising enrollment rates for DURAVYU, EyePoint is poised for a milestone-rich year in 2026. The company's dedication to innovation and patient care sets a strong foundation for future success in the retinal disease market.